← Russell 3000 cross-section

SRTA Strata Critical Medical, Inc.

Trailing twelve months to 2026-06-30 · as filed 2026-08-04, not restated
Healthcare

Scale

Market cap
$554m
Revenue TTM
$212m
Net income TTM
$40m
Free cash flow
$-48m
Composite score
33.6
Sector rank
#2357

Valuation

P / E
13.8
EV / EBITDA
EV / sales
2.5
FCF yield
-8.73%
Earnings yield vs 10-yr
2.52pp

Earnings yield vs 10-yr compares what the business earns per pound invested against the 4.73% a 10-year US Treasury note pays for no equity risk. Negative means you are paying up front for growth not yet delivered.

Quality and growth

Net margin
19.0%
EBITDA margin
-0.9%
ROE
14.4%
ROIC
-7.1%
Revenue growth
-16.7%

Insider activity, last 90 days

Net open-market
$-0.45m
Buyers
0
Sellers
5

Open-market purchases and sales only. Grants, option exercises, gifts and shares withheld for tax are excluded: they are how people are paid, not what they think.

What management said

In recent years, the supply of donor organs has increased consistently, driven primarily by (i) increased utilization of Donation after Circulatory Death, which has expanded the pool of eligible donors; (ii) advancements in technology, including machine and regional perfusion; and (iii) regulatory changes enabling more efficient allocation of organs to recipients with higher need. Selling, General and Administrative Selling, general and administrative (“SG&A”) expenses consist primarily of: staff costs for employees in the commercial, technology, executive, marketing and administrative functions; sales commissions; stock-based compensation; professional and consulting fees; insurance; facili …Strata Critical Medical, Inc., 10-Q, period ended 2026-06-30, filed 2026-08-04

Read the full passage →